Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

Persistent macular edema is the main cause of irreversible visual impairment in patients with prolonged, uncontrolled uveitis. OCT has become the most frequently used tool to quantitatively ...

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...

For patients devoid of HLA antibodies, this is not an issue. However, for patients with HLA alloantibodies, that is, the sensitized patient, we face significant challenges in assessing the ...

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

In South Africa, one in 15 deaths among those under 75 is caused by cancer, with blood cancer - diagnosed in over 7,300 ...

A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...

After exclusion of synonymous variants, approaching 13 000 variants were found per patient, of which approximately 300 were novel (supplementary table 2). Across all eight exomes, we found 332 ...